Current concepts of pathogenesis and treatment of myasthenia gravis.

[1]  L. Raymond,et al.  DOES HELIUM HÆMOLYSE? , 1980, The Lancet.

[2]  S. Elias,et al.  The role of acetylcholine receptor antibodies in myasthenia gravis. , 1979, Federation proceedings.

[3]  S. Elias,et al.  Neonatal myasthenia gravis in the infant of a myasthenic mother in remission , 1979, Annals of neurology.

[4]  S. Elias,et al.  Acetylcholine receptor in myasthenia gravis: Increased affinity for α‐bungarotoxin , 1978 .

[5]  J. Lindstrom,et al.  Penicillamine‐induced myasthenia gravis associated with antibodies to acetylcholine receptor , 1978, Neurology.

[6]  S. Fuchs,et al.  Specific immunosuppression of experimental autoimmune myasthenia gravis by denatured acetylcholine receptor. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Heinemann,et al.  Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera , 1978, Nature.

[8]  E. F. Stanley,et al.  Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. , 1978, Science.

[9]  B. Patten.  Myasthenia gravis: Review of diagnosis and management , 1978, Muscle & nerve.

[10]  J. Merlie,et al.  Immunization of rats with polypeptide chains from torpedo acetylcholine receptor causes an autoimmune response to receptors in rat muscle. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Lindstrom,et al.  Content of acetylcholine receptor and antibodies bound to receptor in myasthenia gravis, experimental autoimmune myasthenia gravis, and Eaton‐Lambert syndrome , 1978, Neurology.

[12]  R. Miledi,et al.  Acetylcholine-induced channels and transmitter release at human endplates , 1978, Nature.

[13]  J. Lindstrom,et al.  Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. , 1977, The New England journal of medicine.

[14]  R. Anwyl,et al.  Myasthenia gravis serum reduces acetylcholine sensitivity in cultured rat myotubes , 1977, Nature.

[15]  R. Anwyl,et al.  Accelerated degradation of acetylcholine receptor from cultured rat myotubes with myasthenia gravis sera and globulins. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Engel,et al.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.

[17]  D. Drachman,et al.  Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. , 1977, Science.

[18]  A. Engel,et al.  A new myasthenic syndrome with end‐plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release , 1977, Annals of neurology.

[19]  J. Changeux,et al.  Acetylcholine receptor degradation measured by pulse chase labelling , 1976, Nature.

[20]  A. Allison.  Self-tolerance and autoimmunity in the thyroid. , 1976, The New England journal of medicine.

[21]  S H Appel,et al.  EFFECTS OF NORMAL AND MYASTHENIC SERUM FACTORS ON INNERVATED AND CHRONICALLY DENERVATED MAMMALIAN MUSCLES , 1976, Annals of the New York Academy of Sciences.

[22]  A. Pestronk,et al.  Myasthenia gravis: passive transfer from man to mouse , 1975, Science.

[23]  R. Almon,et al.  Acetylcholine receptor antibodies in myasthenia gravis. , 1975, The New England journal of medicine.

[24]  R. Almon,et al.  Interaction of myasthenic serum globulin with the acetylcholine receptor. , 1975, Biochimica et biophysica acta.

[25]  P. Devreotes,et al.  Acetylcholine receptor turnover in membranes of developing muscle fibers , 1975, The Journal of cell biology.

[26]  A. Papatestas,et al.  Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations. , 1975, The American journal of medicine.

[27]  W. Engel,et al.  MYASTHENIA GRAVIS: A SERUM FACTOR BLOCKING ACETYLCHOLINE RECEPTORS OF THE HUMAN NEUROMUSCULAR JUNCTION , 1975, The Lancet.

[28]  B. Zweiman,et al.  The thymus in myasthenia gravis. Evidence for altered cell populations. , 1974, The New England journal of medicine.

[29]  C G Andrew,et al.  Serum Globulin in Myasthenia Gravis: Inhibition of α-Bungarotoxin Binding to Acetylcholine Receptors , 1974, Science.

[30]  H. Oosterhuis,et al.  Myasthenia Gravis, Autoantibodies, and HL-A Antigens , 1974, British medical journal.

[31]  D. Drachman,et al.  Neuromuscular Junction in Myasthenia Gravis: Decreased Acetylcholine Receptors , 1973, Science.

[32]  N. K. Jerne,et al.  The immune system. , 1973, Scientific American.

[33]  G. Genkins,et al.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. , 1971, The Mount Sinai journal of medicine, New York.

[34]  A. Engel,et al.  HISTOMETRIC ANALYSIS OF THE ULTRASTRUCTURE OF THE NEUROMUSCULAR JUNCTION IN MY ASTHENIA GRAVIS AND IN THE MYASTHENIC SYNDROME * , 1971, Annals of the New York Academy of Sciences.

[35]  B. Castleman.  THE PATHOLOGY OF THE THYMUS GLAND IN MYASTHENIA GRAVIS , 1966, Annals of the New York Academy of Sciences.

[36]  B. Seegal,et al.  Immunofluorescence Demonstration of a Muscle Binding, Complement-Fixing Serum Globulin Fraction in Myasthenia Gravis. ∗ , 1960 .

[37]  J. Simpson.  Myasthenia Gravis: A New Hypothesis , 1960 .

[38]  C. B. Weinberg,et al.  Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. , 1979, Proceedings of the National Academy of Sciences of the United States of America.